Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
Vigneswaran, Janani; Tan, Yi-Hung Carol; Murgu, Septimiu D; Won, Brian M; Patton, Kathryn Alexa; Villaflor, Victoria M; Hoffman, Philip C; Hensing, Thomas; Hogarth, D Kyle; Malik, Renuka; MacMahon, Heber; Mueller, Jeffrey; Simon, Cassie A; Vigneswaran, Wickii T; Wigfield, Christopher H; Ferguson, Mark K; Husain, Aliya N; Vokes, Everett E; Salgia, Ravi.
; 7(14): 18876-86, 2016 Apr 05.
Artigo em Inglês | MEDLINE | ID: mdl-26934441
Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers.
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.
Detection of an EGFR mutation in cytological specimens of lung adenocarcinoma.
Diagnose, Prognose und Prädiktion nicht-kleinzelliger Lungenkarzinome. Bedeutung von Morphologie, Immunhistochemie und Molekularpathologie.
CIP4 promotes lung adenocarcinoma metastasis and is associated with poor prognosis.
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
The role of the cytopathologist in subtyping and epidermal growth factor receptor testing in non-small cell lung cancer: An institutional experience.
Newly Diagnosed Lung Cancer: Which Molecular Tests Are Needed for Optimal Treatment Decision Making?
Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis.